Abstract
A patient with Guillain-Barre syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barre syndrome such as interleukin-2, interferon-γ, and tumor necrosis factor-α. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.
| Original language | English |
|---|---|
| Pages (from-to) | 266-268 |
| Number of pages | 3 |
| Journal | Journal of Neurology, Neurosurgery and Psychiatry |
| Volume | 65 |
| Issue number | 2 |
| Publication status | Published - 1998 |
Fingerprint
Keywords
- Autoimmunity
- Cytokines
- Fucidin
- Guillian-Barre syndrome
ASJC Scopus subject areas
- Neuropsychology and Physiological Psychology
- Neuroscience(all)
- Psychiatry and Mental health
Cite this
Sodium fusidate in Gillain-Barre syndrome : A case report. / Nicoletti, F.; Nicoletti, A.; Giuffrida, S.; Di Marco, R.; Meroni, P. L.; Bendtzen, K.; Lunetta, M.
In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 65, No. 2, 1998, p. 266-268.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sodium fusidate in Gillain-Barre syndrome
T2 - A case report
AU - Nicoletti, F.
AU - Nicoletti, A.
AU - Giuffrida, S.
AU - Di Marco, R.
AU - Meroni, P. L.
AU - Bendtzen, K.
AU - Lunetta, M.
PY - 1998
Y1 - 1998
N2 - A patient with Guillain-Barre syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barre syndrome such as interleukin-2, interferon-γ, and tumor necrosis factor-α. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.
AB - A patient with Guillain-Barre syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barre syndrome such as interleukin-2, interferon-γ, and tumor necrosis factor-α. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.
KW - Autoimmunity
KW - Cytokines
KW - Fucidin
KW - Guillian-Barre syndrome
UR - http://www.scopus.com/inward/record.url?scp=0031824966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031824966&partnerID=8YFLogxK
M3 - Article
C2 - 9703187
AN - SCOPUS:0031824966
VL - 65
SP - 266
EP - 268
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
SN - 0022-3050
IS - 2
ER -